Skip to main content
Top
Published in: BMC Gastroenterology 1/2024

Open Access 01-12-2024 | Hepatocellular Carcinoma | Research

The impact of Karnofsky performance status on prognosis of patients with hepatocellular carcinoma in liver transplantation

Authors: Jie Zhou, Danni Ye, Siyao Zhang, Jiawei Ding, Tao Zhang, Zheng Chen, Fangshen Xu, Shenli Ren, Zhenhua Hu

Published in: BMC Gastroenterology | Issue 1/2024

Login to get access

Abstract

Background

Functional performance as measured by the Karnofsky Performance Status (KPS) scale has been linked to the outcomes of liver transplant patients; however, the effect of KPS on the outcomes of the hepatocellular carcinoma (HCC) liver transplant population has not been fully elucidated. We aimed to investigate the association between pre-transplant KPS score and long-term outcomes in HCC patients listed for liver transplantation.

Methods

Adult HCC candidates listed on the Scientific Registry of Transplant Recipients (SRTR) database from January 1, 2011 to December 31, 2017 were grouped into group I (KPS 80–100%, n = 8,379), group II (KPS 50–70%, n = 8,091), and group III (KPS 10–40%, n = 1,256) based on percentage KPS score at listing. Survival was compared and multivariable analysis was performed to identify independent predictors.

Results

Patients with low KPS score had a higher risk of removal from the waiting list. The 5-year intent-to-treat survival was 57.7% in group I, 53.2% in group II and 46.7% in group III (P < 0.001). The corresponding overall survival was 77.6%, 73.7% and 66.3% in three groups, respectively (P < 0.001). Multivariable analysis demonstrated that KPS was an independent predictor of intent-to-treat survival (P < 0.001, reference group I; HR 1.19 [95%CI 1.07–1.31] for group II, P = 0.001; HR 1.63 [95%CI 1.34–1.99] for group III, P < 0.001) and overall survival(P < 0.001, reference group I; HR 1.16 [95%CI 1.05–1.28] for group II, P = 0.004; HR 1.53 [95%CI 1.26–1.87] for group III, P < 0.001). The cumulative 5-year recurrence rates was higher in group III patients (7.4%), compared with 5.2% in group I and 5.5% in group II (P = 0.037). However, this was not significant in the competing regression analysis.

Conclusions

Low pre-transplant KPS score is associated with inferior long-term survival in liver transplant HCC patients, but is not significantly associated with post-transplant tumor recurrence.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.CrossRefPubMedPubMedCentral Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.CrossRefPubMedPubMedCentral
2.
go back to reference Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transpl. 2014;14(8):1870–9.CrossRef Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transpl. 2014;14(8):1870–9.CrossRef
3.
go back to reference Orman ES, Ghabril M, Chalasani N. Poor performance status is Associated with increased mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2016;14(8):1189–95. e1.CrossRefPubMedPubMedCentral Orman ES, Ghabril M, Chalasani N. Poor performance status is Associated with increased mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2016;14(8):1189–95. e1.CrossRefPubMedPubMedCentral
4.
go back to reference Jacob M, Copley LP, Lewsey JD, Gimson A, Rela M, van der Meulen JH, et al. Functional status of patients before liver transplantation as a predictor of posttransplant mortality. Transplantation. 2005;80(1):52–7.CrossRefPubMed Jacob M, Copley LP, Lewsey JD, Gimson A, Rela M, van der Meulen JH, et al. Functional status of patients before liver transplantation as a predictor of posttransplant mortality. Transplantation. 2005;80(1):52–7.CrossRefPubMed
5.
go back to reference Wallace D, Cowling T, McPhail MJ, Brown SE, Aluvihare V, Suddle A, et al. Assessing the time-dependent impact of performance status on outcomes after Liver Transplantation. Hepatology. 2020;72(4):1341–52.CrossRefPubMed Wallace D, Cowling T, McPhail MJ, Brown SE, Aluvihare V, Suddle A, et al. Assessing the time-dependent impact of performance status on outcomes after Liver Transplantation. Hepatology. 2020;72(4):1341–52.CrossRefPubMed
6.
go back to reference He J, Zeng ZC, Fan J, Zhou J, Sun J, Chen B, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation. BMC Cancer. 2011;11:492.CrossRefPubMedPubMedCentral He J, Zeng ZC, Fan J, Zhou J, Sun J, Chen B, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation. BMC Cancer. 2011;11:492.CrossRefPubMedPubMedCentral
7.
go back to reference Samoylova ML, Dodge JL, Vittinghoff E, Yao FY, Roberts JP. Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database. Liver Transpl. 2013;19(12):1318–23.CrossRefPubMedPubMedCentral Samoylova ML, Dodge JL, Vittinghoff E, Yao FY, Roberts JP. Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database. Liver Transpl. 2013;19(12):1318–23.CrossRefPubMedPubMedCentral
8.
go back to reference Orci LA, Berney T, Majno PE, Lacotte S, Oldani G, Morel P, et al. Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation. Br J Surg. 2015;102(10):1250–7.CrossRefPubMed Orci LA, Berney T, Majno PE, Lacotte S, Oldani G, Morel P, et al. Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation. Br J Surg. 2015;102(10):1250–7.CrossRefPubMed
9.
go back to reference Wileyto EP, Li Y, Chen J, Heitjan DF. Assessing the fit of parametric cure models. Biostatistics. 2013;14(2):340–50.CrossRefPubMed Wileyto EP, Li Y, Chen J, Heitjan DF. Assessing the fit of parametric cure models. Biostatistics. 2013;14(2):340–50.CrossRefPubMed
10.
go back to reference Hess KR. Assessing time-by‐covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med. 1994;13(10):1045–62.CrossRefPubMed Hess KR. Assessing time-by‐covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med. 1994;13(10):1045–62.CrossRefPubMed
11.
go back to reference Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.MathSciNetCrossRef Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.MathSciNetCrossRef
12.
go back to reference Ortman JM, Velkoff VA, Hogan H. An aging nation: the older population in the United States. US Census Bureau. 2014:25–1140. Ortman JM, Velkoff VA, Hogan H. An aging nation: the older population in the United States. US Census Bureau. 2014:25–1140.
13.
go back to reference Durand F, Levitsky J, Cauchy F, Gilgenkrantz H, Soubrane O, Francoz C. Age and liver transplantation. J Hepatol. 2019;70(4):745–58.CrossRefPubMed Durand F, Levitsky J, Cauchy F, Gilgenkrantz H, Soubrane O, Francoz C. Age and liver transplantation. J Hepatol. 2019;70(4):745–58.CrossRefPubMed
14.
go back to reference Malinis MF, Chen S, Allore HG, Quagliarello VJ. Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) era. Ann Transpl. 2014;19:478–87.CrossRef Malinis MF, Chen S, Allore HG, Quagliarello VJ. Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) era. Ann Transpl. 2014;19:478–87.CrossRef
15.
go back to reference Thuluvath PJ, Thuluvath AJ, Savva Y. Karnofsky performance status before and after liver transplantation predicts graft and patient survival. J Hepatol. 2018;69(4):818–25.CrossRefPubMed Thuluvath PJ, Thuluvath AJ, Savva Y. Karnofsky performance status before and after liver transplantation predicts graft and patient survival. J Hepatol. 2018;69(4):818–25.CrossRefPubMed
16.
go back to reference Thuluvath PJ, Thuluvath AJ, Savva Y, Zhang T. Karnofsky Performance Status following liver transplantation in patients with multiple organ failures and probable Acute-on-chronic liver failure. Clin Gastroenterol Hepatol. 2020;18(1):234–41.CrossRefPubMed Thuluvath PJ, Thuluvath AJ, Savva Y, Zhang T. Karnofsky Performance Status following liver transplantation in patients with multiple organ failures and probable Acute-on-chronic liver failure. Clin Gastroenterol Hepatol. 2020;18(1):234–41.CrossRefPubMed
17.
go back to reference Tapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Lai M. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. Hepatology. 2015;62(2):584–90.CrossRefPubMed Tapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Lai M. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. Hepatology. 2015;62(2):584–90.CrossRefPubMed
18.
go back to reference Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl. 2010;16(12):1373–8.CrossRefPubMed Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl. 2010;16(12):1373–8.CrossRefPubMed
19.
go back to reference Englesbe MJ. Quantifying the eyeball test: Sarcopenia, analytic morphomics, and liver transplantation. Liver Transpl. 2012;18(10):1136–7.CrossRefPubMed Englesbe MJ. Quantifying the eyeball test: Sarcopenia, analytic morphomics, and liver transplantation. Liver Transpl. 2012;18(10):1136–7.CrossRefPubMed
20.
go back to reference Derck JE, Thelen AE, Cron DC, Friedman JF, Gerebics AD, Englesbe MJ, et al. Quality of life in liver transplant candidates: frailty is a better indicator than severity of liver disease. Transplantation. 2015;99(2):340–4.CrossRefPubMed Derck JE, Thelen AE, Cron DC, Friedman JF, Gerebics AD, Englesbe MJ, et al. Quality of life in liver transplant candidates: frailty is a better indicator than severity of liver disease. Transplantation. 2015;99(2):340–4.CrossRefPubMed
21.
go back to reference Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002–7.CrossRefPubMed Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002–7.CrossRefPubMed
22.
go back to reference Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187–93.CrossRefPubMed Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187–93.CrossRefPubMed
23.
go back to reference Peus D, Newcomb N, Hofer S. Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. BMC Med Inf Decis Mak. 2013;13:72.CrossRef Peus D, Newcomb N, Hofer S. Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. BMC Med Inf Decis Mak. 2013;13:72.CrossRef
24.
go back to reference Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude Et de Traitement Du Carcinome Hepatocellulaire. J Hepatol. 1999;31(1):133–41.CrossRefPubMed Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude Et de Traitement Du Carcinome Hepatocellulaire. J Hepatol. 1999;31(1):133–41.CrossRefPubMed
25.
go back to reference Liu L, Miao R, Yang H, Lu X, Zhao Y, Mao Y, et al. Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. Am J Surg. 2012;203(6):741–50.CrossRefPubMed Liu L, Miao R, Yang H, Lu X, Zhao Y, Mao Y, et al. Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. Am J Surg. 2012;203(6):741–50.CrossRefPubMed
26.
go back to reference Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.CrossRefPubMed Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.CrossRefPubMed
27.
go back to reference Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–403.CrossRefPubMed Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–403.CrossRefPubMed
28.
go back to reference Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut. 2016;65(6):1035–41.CrossRefPubMed Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut. 2016;65(6):1035–41.CrossRefPubMed
29.
go back to reference Lai JC, Segev DL, McCulloch CE, Covinsky KE, Dodge JL, Feng S. Physical frailty after liver transplantation. Am J Transpl. 2018;18(8):1986–94.CrossRef Lai JC, Segev DL, McCulloch CE, Covinsky KE, Dodge JL, Feng S. Physical frailty after liver transplantation. Am J Transpl. 2018;18(8):1986–94.CrossRef
30.
go back to reference Lai JC, Sonnenday CJ, Tapper EB, Duarte-Rojo A, Dunn MA, Bernal W, et al. Frailty in liver transplantation: an expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am J Transpl. 2019;19(7):1896–906.CrossRef Lai JC, Sonnenday CJ, Tapper EB, Duarte-Rojo A, Dunn MA, Bernal W, et al. Frailty in liver transplantation: an expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am J Transpl. 2019;19(7):1896–906.CrossRef
Metadata
Title
The impact of Karnofsky performance status on prognosis of patients with hepatocellular carcinoma in liver transplantation
Authors
Jie Zhou
Danni Ye
Siyao Zhang
Jiawei Ding
Tao Zhang
Zheng Chen
Fangshen Xu
Shenli Ren
Zhenhua Hu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2024
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-024-03161-7

Other articles of this Issue 1/2024

BMC Gastroenterology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.